Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 3 · 42.9%Low 0 · 0%Moderate 2 · 28.6%High 0 · 0%

Rituximab vs other disease‐modifying treatments

Comparison intervention · relapsing multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rituximab vs other disease‐modifying treatments

Interferons or glatiramer acetate · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes interferons or glatiramer acetate compared with other disease‐modifying treatments (very low certainty).

1 finding from 1 review

Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
HR 0.86 [0.52, 1.42]
853 participants
Very low

Rituximab vs other disease‐modifying treatments

Fingolimod (Direct evidence; 2 RCTs; 2355 participants) · relapsing multiple sclerosis

Rituximab as 'switching' probably leads to lower fingolimod compared with other disease‐modifying treatments (moderate certainty).

1 finding from 1 review

Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
HR 0.08 [0.02, 0.32]
256 participants
Moderate

Rituximab vs other disease‐modifying treatments

Natalizumab · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes natalizumab compared with other disease‐modifying treatments (very low certainty).

1 finding from 1 review

Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
HR 1 [0.2, 5]
153 participants
Very low

Rituximab vs other disease‐modifying treatments

— · relapsing multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rituximab vs other disease‐modifying treatments

Interferon beta or glatiramer acetate · relapsing multiple sclerosis

Rituximab as 'switching' probably leads to higher interferon beta or glatiramer acetate compared with other disease‐modifying treatments (moderate certainty).

1 finding from 1 review

Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
OR 1.71 [1.11, 2.62]
5477 participants
Moderate

Rituximab vs other disease‐modifying treatments

Ocrelizumab · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes ocrelizumab compared with other disease‐modifying treatments (very low certainty).

1 finding from 1 review

Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
OR 0.02 [0, 0.4]
472 participants
Very low